ロード中...
Elagolix: First Global Approval
Elagolix (ORILISSA™), an orally bioavailable, second-generation, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist, is being developed AbbVie and Neurocrine Biosciences for the treatment of reproductive hormone-dependent disorders in women. In July 2018, the US FDA approved elago...
保存先:
| 出版年: | Drugs |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6244606/ https://ncbi.nlm.nih.gov/pubmed/30194661 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-018-0977-4 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|